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Objective: We sought to systematically review the literature on the psychiatric risk of 
offspring of parents with bipolar disorder (OPBD) using a developmental 
psychopathology framework. The review also sought to establish the utility of clinical 
stage modelling as a framework for identifying precursor disorders to later onset of 
bipolar disorder (BD) in OPBDs.  
Methods: A systematic search was performed using EMBASE, PsychINFO and 
Medline. Reference lists of included studies and previous reviews were also searched. 
Studies were included if they reported diagnostic outcomes for children, adolescents 
and young adult offspring of parents diagnosed with BD.  
Results: Twenty-six studies were identified representing 21 individual cohorts. The 
review identified that OBPD present as a high-risk group for a range of mood and 
non-mood disorders in childhood, adolescence and young adulthood. The trajectory of 
risk was from non-mood disorders in childhood via mood disorders in early 
adolescence towards mania/hypomania in late adolescence and early adulthood. From 
a clinical staging perspective, childhood anxiety disorders were associated with later 
onset of BD. Recurrent substance use disorder was identified as a risk in OPBD 
during late adolescence and early adulthood. Quality ratings indicated studies were 
methodologically robust. 
Conclusions: Our review provides evidence for a developmental psychopathology 
trajectory of precursor risks to BD in OPBD. There is support for clinical stage 
modelling as a conceptual framework for understanding developmental risk in OPBD 
and as a tool for developing early and individualized intervention strategies.  
 









Bipolar disorder (BD) is a chronic mood disorder characterised by episodes of mania 
or hypomania alternating with depression, with significant comorbidity, suicide risk, 
interpersonal, societal and economic costs (1-6). Retrospective reports suggest that the 
majority of individuals experience the first symptoms of BD prior to adulthood (7), 
with a mean age of onset estimated to be between late adolescence and early 
adulthood (8). More than half of BD patients report either under-diagnosis or 
misdiagnosis prior to index diagnosis of BD, with duration of untreated illness of up 
to 10 years (9,10). Improving the understanding of early, prodromal stages of BD 
through the delineation of high-risk sub-groups (as in non-affective psychosis; 11) has 
implications for improving the precision of BD diagnosis, expanding early 
intervention strategies and generating primary prevention strategies (12,13).  
Risk of Psychopathology in OPBD  
One approach to identification of early stage BD is through assessment of 
developmental pathways of cohorts at high-risk for developing BD – or offspring of 
parents with bipolar disorder (OPBD). Evidence from family, twin, and adoption 
studies suggest a heritability rate of up to 85% in monozygotic twins (14) and a 5-to-
10-fold higher prevalence of BD amongst first-degree relatives compared to the 
general population (15). Population cohort data suggests that offspring of two BD-
diagnosed parents have a 5.7-fold higher risk of developing BD compared to offspring 
with only one bipolar parent, and a 51.9-fold risk compared to offspring with no 
bipolar parents (16). The significantly elevated risk of BD in OPBD raises the 
question of whether, within this risk trajectory, there are both distinct “ultra-high risk 
endophenotypes” and whether OBPD who go on to develop BD progress through 
recognizable clinical stages en-route to a later diagnosis (17). 
It is also increasingly apparent, that in addition to elevated risk of later BD, OBPD 
present with an elevated risk of a broad spectrum of mood and non-mood disorders 
(5,18). Meta-analytic estimates indicate a 2.7-fold increased risk of any mental health 
disorder and a 4-fold risk for any affective disorder in OBPD compared to offspring 
of healthy parents. However, these estimates are largely derived from historical 
cohorts identified in the previous century (19). The risk profile of OBPD also appears 
to be distinct from trajectory of risk for offspring of parents with major mood 
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disorders (20) or non-affective psychoses (21). This suggests that the risk 
endophenotypes in OBPD is not reducible to a generalised risk attributable to being 
raised by a parent with a mental health disorder (22), but may represent a specific 
vulnerability linked to OPBD status.  
Although there is growing evidence that a substantial proportion of OBPD will 
develop at least one psychiatric disorder (23-26), there is scant evidence regarding the 
developmental progression of the syndromes presented in this cohort (27,28) and the 
existing literature is inconsistent with regard to the specificity of risk in OBPD (29). 
Data on protective factors are also very limited.  
Developmental Modelling of OPBD Risk 
Developmental modelling of risk of onset of BD highlights the importance of 
depressive, anxiety and/or behavioural disorders as potential precursors to BD in 
OPBD (30). However, these precursor disorders are neither necessary for, or specific 
to development of BD in OPBD. Indeed, existing longitudinal data on OPBD 
outcomes across different developmental periods reports diverse patterns with regards 
to continuity/discontinuity and specificity of psychopathology between different 
developmental stages. These findings indicate significant increases in the onset of 
depressive, anxiety and behavioural problems from early to late childhood (31), but 
very few new onset, recurrent and chronic disorders are reported from early to late 
adolescence (32). Ten -year longitudinal data also suggests developmental 
discontinuity in internalising problems in OPBD from early childhood to late 
adolescence, with these difficulties being expressed differently across periods, e.g. 
self-regulatory deficits in childhood through to thought problems (28). Longitudinal 
studies reporting prospective data for cohorts followed through different 
developmental stages, and data incorporating the peak risk point for BD onset (early 
adulthood) have only recently emerged (23,27,21,33). Consequently, it is unclear 
whether the presence of other disorders in this cohort represent early risk phenotypes, 
comorbid conditions, or early expressions of BD (e.g. ADHD; 29). In addition, the 
OPBD literature is hampered by methodological differences in terms of cross-
sectional versus longitudinal designs, differences in assessment tools and sample 
recruitment (17), and differences in health care systems and provision (33,34).  
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As such the current ‘state of the art’ offers inconclusive findings regarding the 
predictive association of mood or non-mood disorders with the development of BD in 
OPBD. In addition, the issue of identification and treatment of psychopathology in 
OBPD raises a number of ethical questions, including whether identification of 
putative risk endophenotypes are sufficient and specific enough to merit early 
treatment with psychotropic medication (35), and whether identification using an 
endophenotype increases risk of false-positive diagnoses. 
Clinical Stage Modelling: A Developmental Psychopathology Framework 
One heuristic framework to improve the modelling of risk and onset of 
psychopathology is clinical staging. This framework proposes that disorders develop 
through a predictable temporal pathway and that stage-appropriate treatment can 
modify and potentially prevent such course (36,37). These models are usually 
conceptualised as stages, evolving from an at-risk stage (Stage 0; e.g. genetic 
predisposition) to an end-stage (Stage 4; e.g. highly severe and poor prognostic 
presentation of a disorder; 38); albeit with the understanding that all stages have an 
indicative character and may not describe the clinical course for any given individual 
(39). Consequently, clinical staging has been identified as a promising approach in 
understanding the risk endophenotype in OPBD (27,40,41);  with a recent review of 
BD staging in adulthood highlighting its utility, evidence-based focus and 
dissemination to clinical settings (42).  
To date, staging models of BD primarily apply two approaches for describing the 
progression of risk, focusing on either number of episodes (43) or on level of 
functioning (44,45). In both approaches the emphasis is mainly on the progress of the 
illness following the onset of manic-depressive symptoms and only in adult 
populations. In contrast, Duffy and colleagues (27,40,41) apply a clinical staging 
model focused on child and adolescent OPBD evaluated from before the onset of the 
first manic/hypomanic episode. As illustrated in Figure 1, this staging model 
progresses from a ‘well’ state (no presentation of mental health disorders; Stage 0), to 
the onset of non-mood disorders (Stage 1; e.g. anxiety, sleep disorders), followed by 
the onset of minor mood disorders (Stage 2; e.g. adjustment disorders) in childhood. 
The next stage is characterised by the development of major mood disorders (Stage 3; 
major mood depression) in adolescence, and ultimately the onset of the first 
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manic/hypomanic episode during late adolescence/ early adulthood (Stage 4). This 
model also suggests a recurrent substance use disorder across the last two stages. 
Although this developmental psychopathology model offers a framework for 
delineating the developmental progression of BD in OPBD, it is based in findings 
from only one cohort. Therefore, it remains unclear whether this developmental 
pathway is generalizable to other at-risk OPBD cohorts. In addition, clinical staging in 
OBPD is based on trajectories towards an end-state of BD, and may not encompass 
risk of other psychiatric disorders as end-states. However, this is to be balanced 
against the promise of clinical staging as a tool for integrating early, family informed 
assessment of risk, and of the potential for the introduction of early intervention 
strategies that have a positive risk/benefit ratio for young people (e.g. psychological 
interventions or family therapies). 
Aims of Review 
Based on the existing evidence of increased risk of BD in OPBD, and of the presence 
of precursor disorders within the pathway to disorder, the aim of the current review 
was to systematically review and synthesise the existing literature on psychiatric risk 
in OPBD. In addition, where applicable, these data were compared to the clinical 
staging model of OPBD (40) with the aim of identifying an ultra-high-risk OPBD 
endophenotype. Specifically, we sought to establish whether there is a distinct pattern 
of psychiatric risk in OPBD; to establish how this risk profile differs according to 
developmental stage; and to evaluate whether a clinical staging model could provide a 




This systematic review was registered in PROSPERO (registration number: 
42016048333; 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016048333). 
Conduct and reporting of the systematic review followed PRISMA guidelines (59). A 
search strategy was conducted independently by two reviewers (AR, SO) for articles 
published in peer-reviewed journals from 1970 to May 2016 and in press using the 
following electronic databases: EMBASE (1974-May 2016), PsychINFO (1806-April 
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2016) and Medline (1946- April 2016). Investigation was facilitated by OVID multi-
field search. Hard copies were sought when necessary. After consultation with a 
librarian, the following terms were used to identify eligible papers: (child* or 
offspring* or son* or daughter*) AND (bipolar or mania or manic-depress*) adj5 
(parent* or mother* or father*). No term was applied regarding the outcome of the 
studies (e.g. psychopathology or risk), to avoid elimination of studies due to word 
bias. Truncation (*) and adjacency operator (“adj5”) were employed to increase 
search sensitivity. Citations from the initial research were de-duplicated. Full search 
history is reported in the Supplemental Material (Table 6). A leakage strategy was 
implemented through screening reference lists of all the eligible papers and existing 
narrative (12) and related systematic reviews (17-19,29,47). 
Study Selection 
Studies were included if they reported (i) a diagnostic assessment of BD in parent(s) 
based on a clinical interview; (ii) measures of psychopathology in offspring of 
parent(s) with BD based on Diagnostic and Statistical Manual (DSM); and (iii) a 
mean age of offspring below 18 years old at initial point of offspring psychiatric 
assessment (where studies reported on longitudinal follow-up studies, mean age was 
judged from the mean age at first assessment, but further follow-up points were 
included). Papers were eligible for inclusion if they were (iv) published in peer-
reviewed journals, and (v) conducted between 1970 and May 2016.  
Papers were excluded if they reported (i) on first degree relatives or members of 
extended families without distinguishing the offspring outcomes based on the relation 
to the affected member. This exclusion was used to ensure papers were focused on 
parent-offspring risk, rather than broad genetic risks. Papers were also excluded if (ii) 
reporting solely on dimensional outcomes in offspring. This was set to ensure a 
homogeneous and validated base of comparison between studies in terms of 
outcomes. (iii) Single or family case reports; (iv) book chapters, protocols, comments, 
corrections; and (v) previous systematic reviews and meta-analyses were also 
excluded.  
Once titles and abstracts were screened, full texts of potentially eligible papers were 
examined. Where multiple papers were published from the same cohort, the article 
reporting most recent follow-up was selected. If remaining papers from these multi-
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paper cohorts provided supplementary information about the cohort, they were also 
included. Some of these cohorts also reported follow-up points beyond the cohort 
mean age of 18 years. Consequently, for completeness, we reported these data for 
young adulthood and adulthood in our results. Accuracy of the final list of papers was 
confirmed by the independent reviewer SO and any disagreements resolved by 
consensus agreement with the third researcher (AM).  
Data Extraction 
Data were initially extracted per study and subsequently grouped per cohort. The 
following information was included in the final data collection: name of cohort and 
name of first author, year of publication, country of origin, parental characteristics 
(number and gender), offspring characteristics (number, gender and mean age), 
assessment characteristics (type of diagnostic criteria used, assessment tool used in 
parents, assessment tool used in offspring), design of study (cross-sectional or 
longitudinal, including the follow-up duration measured in years) and, if any, type of 
control group (i.e. offspring of healthy and/or psychiatrically ill parents).  
Cohort findings were synthesized based on two developmental frameworks. In the 
first, cohorts were divided into five developmental stages based on the mean age of 
their sample: early childhood (0-6 y.o.); middle childhood (6-12 y.o.); adolescence 
(12-18 y.o.); young adulthood (18-23 y.o.) and adulthood (>23 y.o.). Psychiatric 
outcomes in OPBD were obtained in the form of lifetime/ current estimated 
prevalence (%) or cumulative incidence (%) for any Axis I disorder and then further 
distinguished for each mood and non-mood disorder. In the second framework (based 
on Duffy’s clinical staging model, 27,40), available data on the mean age of the onset 
of mood and non-mood disorders were placed on a continuum according to their 
sequential relation to the onset of BD or manic/hypomanic symptoms. Longitudinal 
data reporting on the association between onset of mood and non-mood disorders and 
later onset of BD were also identified. 
Quality Assessment 
Quality assessment was conducted using an adapted version of the Agency for 
Healthcare Research and Quality (AHRQ) checklist (48). The quality check was 
applied to all papers that met inclusion criteria, regardless of the cohort. 
Methodological robustness of the papers was evaluated based on 11 quality criteria. 
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The rating scale is presented in detail in Table 7 (Supplemental Material). The grading 
of each item contained the options ‘Yes’ (2 points), ‘Partially’ (1 point), ‘No’ (0 
points), or ‘Not Applicable’ (N/A). All applicable items were added up to a “Total 
Score”, which was then divided by the “Max Score” (if all items applicable: 22 points, 
if 1 item not applicable: 20 points, if 2 items not applicable: 18 points, etc.), to 
calculate the “Percentage Score”.  
The formula used was:  




Ten of the 26 eligible papers (39%) were independently rated by another member of 
the research team (SO). Inter-rater reliability was computed using “ReCal2”, which 
resulted in a Cohen’s Kappa score of 0.695, indicating a substantial agreement rate 
(49). Any discrepancies were reassessed and a consensus agreement was reached 






Based on the systematic search described above, 1371 citations were identified, of 
which 61 full texts were reviewed. A further 6 articles were detected through hand-
searching of reference lists of included articles. A total of 26 papers met inclusion 
criteria, representing 21 individual cohorts. The study selection process is illustrated 
in Figure 2.    
Cohort Characteristics 
Key study characteristics are presented in Table 1. The total number of the sample 
was measured based on the number of cohorts (for cohorts providing multiple papers, 
only the report with the most participants was considered). The total sample 
comprised n=1332 bipolar parents and n=2022 OPBD individuals. Sample size for 
individual studies ranged from n=7 to n=236 for parents with BD and from n=7 to 
n=391 for OPBD cohorts. In three of the cohorts, OPBD were strictly selected from 
independent families (i.e. one offspring per family). Among those cohorts reporting 
gender distribution, 11 of 19 indicated an equal male/female ratio (±10%) for BD 
parents and 16 of 20 indicated similarly equal distributions for OPBD. Males were the 
minority in almost all remaining cohorts. Included cohorts represented data from 8 
countries: USA (k=13, including the Amish cohort), Canada (k=1), Netherlands 
(k=1), Switzerland (k=1), Spain (k=2), Turkey (k=1), Brazil (k=1) and Romania 
(k=1).  
With regards to study design, 13 of the 21 cohorts had a cross-sectional design, 6 had 
a longitudinal design, and 2 cohorts generated reports using both designs. OPBD 
follow-up duration extended from 1 to 16 years beyond the index psychiatric 
assessment of offspring, therefore some samples exceeded the mean age of 18 years at 
the last assessment. The mean age of offspring ranged from 2.4 to 28 years old. Of the 
16  cohorts with a control group, 10 were recruited from healthy parents (“healthy 
control group”), 1 from psychiatrically ill parents (“psychiatrically ill control group”) 
and 5 from both (“both types control group”).  
Results from cohort studies were published between 1985 and 2016. This was 
reflected in the categorical measurement used: DSM-III or DSM-III-R (k=6), DSM -
IV or DSM-IV-TR (k=14) and adaptation to both (k=1). Parental and offspring 
assessment tools differed slightly for each cohort, with SCID, SADS and K-SADS 
11 
 
being the predominant measures. There was considerable variability in how specific 
disorders were grouped in individual papers. Therefore, for our narrative synthesis, 
we generated a heuristic framework to map specific disorders into broad psychiatric 
categories. This is presented in Table 2. Six cohorts provided data for all diagnostic 
categories. The remaining cohorts provided data on some but not all the categories of 
psychiatric disorders covered in our review. Study findings were reported in the form 
of current prevalence (k=1), lifetime prevalence (k=19), cumulative incidence (k=2) 
or both lifetime and cumulative incidence (k=4; see Table 3).  
Axis I Disorders across all Developmental Stages 
Diagnostic data were available from all 21 cohorts, with 15 of the 21 cohorts reported 
data on the overall percentage of OPBD presenting with at least one DSM-III-or-IV 
Axis I diagnosis (Table 3; 
23/50/51,32,61,24,13,26,60,20,57,21,59,34,58,62,53/33/52).). The remaining 6 
cohorts reported data on DSM diagnoses, but did not correct for comorbid diagnoses, 
therefore a total percentage could not be generated (REFS).  Approximately 50% of 
OPBD individuals in the majority of cross-sectional studies (21,26,34,50,57,58,60,62) 
and over 70% in longitudinal studies (23,32,33) were assessed as meeting criteria for 
at least one Axis I disorder. This risk was found to be elevated in OPBD when 
compared to offspring of healthy parents, regardless of developmental stage and 
country of origin (20,21,23,24,34,50,51,57,58,59). In the cohorts with a 
psychiatrically ill control group, 2 studies reported OPBD as having a greater rate of 
Axis I disorders (60,62), while 2 studies reported no difference between the two 
groups (20,21). Data for proportion of OBPD meeting criteria for mood and non-
mood related disorders are reported in Table 3, further delineated by developmental 
period.  
Early Childhood 
Five cohorts (31,51,32,61,20) provided data for early childhood, with a mean age 
range from 2.4 (31) to 6 (20) years old. One cohort (51) had a healthy control group 
and one cohort (31) examined its sample at two time points (at a mean age of 2.4 and 




Bipolar Spectrum Disorders (BPSD). A rate of 2% for BD not otherwise specified 
in OPBD was reported (51), which did not significantly differ from offspring of 
healthy parents.  
Unipolar Spectrum Disorders (UPSD). The estimated prevalence in OPBD ranged 
from 0% (31) to 43% (61), which was not found to be significantly different from the 
healthy control group (51). Longitudinal analyses (31) showed a significant increase 
of depression incidence rates among OPBD over the course of early childhood.  
Non-Mood Disorders 
Anxiety Disorders (AD). The prevalence in OPBD ranged from 9% (31) to 43% (61). 
Only the prevalence of generalized anxiety disorder (GAD; 51) was found to be 
significantly higher in OPBD compared to the healthy control group. Longitudinal 
analyses (31) did not show a significant impact of time on OPBD’s incidence rates of 
anxiety (mainly separation anxiety disorder: SAD). 
Disruptive Behaviour Disorders (DBD). The prevalence rate ranged from 2% (51) 
to 43% (61) in OPBD. DBD (as a category, but also separately for attention deficit 
hyperactivity disorder and marginally for oppositional defiant disorder) were found to 
be more prevalent in OPBD compared to the control group (51). An increase in the 
incidence rates of OPBD’s disruptive behaviour was observed during this 
developmental stage (31).  
In all diagnostic categories (except for BPSD), the highest rate was reported by the 
Rockville cohort (61), which had a noticeably smaller sample size than the other 
cohorts (n=7 OPBD).  
Country of origin 
One of the 5 cohorts in this stage had a non-USA sample (20). No differences 
between non-USA and USA cohorts were observed.  
Middle Childhood 
Ten cohorts (31,55,25,32,24,13,26,60,20,50) provided data for the stage of middle 
childhood, with a mean age range from 6.4 (31) to 11.9 (50) years old. Four cohorts 
had a healthy control group (25,24,13,50) and three cohorts had a control group of 
both types (55,60,20). One cohort (31) examined its sample at two time points (at a 




BPSD. The estimated prevalence in OPBD ranged from 2% (60) to 74% (13) and 
from 2% (20,50) to 37% (13) in cohorts specifically reporting for bipolar type-I 
disorder (BD-I). In both cases, the higher percentage belonged to the Cleveland cohort 
(13), which recruited its OPBD sample via clinical settings (i.e. in this cohort the 
offspring rather than the parents were presenting in clinical settings for treatment as 
opposed to most of the other included studies). The prevalence range without this 
cohort was 2% (60) to 38% (24) and 2% (20,50) to 16% (24) respectively. Five 
cohorts found a significantly higher prevalence of BPSD (55,24,13,50) and BD-I 
(55,25,50) in OPBD compared to the healthy control group. Two cohorts (60, 20) 
found no differences between the rates of OPBD and of healthy control group. Three 
cohorts found no differences between the rates of OPBD and of psychiatrically ill 
control groups (55,60,20). 
UPSD. The prevalence rate in OPBD ranged from 5% (60) to 44% (31). Major 
depressive disorder (MDD) ranged from 2% (50) to 14% (24) and minor depressive 
disorders (i.e. dysthymia, adjustment disorder with depressed mood, depression not 
otherwise specified) from 6% (32) to 19% (20). In 2 cohorts, the OPBD’s rates for 
any UPSD (25,20) and specifically for MDD (20,50) were higher compared to the 
healthy control group. In 5 cohorts, OPBD’s rates for any UPSD were not found to be 
significantly higher compared to the healthy (55,24,13,60) and the psychiatrically ill 
(55,60,20) control groups. One cohort (31) reported a significant effect of time (i.e. an 
increase of depressive symptoms in OPBD during this developmental stage). 
Non-Mood Disorders 
AD. The estimated prevalence in OPBD ranged from 1% (13) to 44% (55,60). In 2 of 
the 4 cohorts with a healthy control group the prevalence of any AD was significantly 
higher in OPBD (25,50). In 2 of the 3 cohorts with both types of control group (55,60) 
OPBD presented a significantly higher prevalence of any AD when separately 
compared with offspring of psychiatrically ill parents and with offspring of healthy 
parents; meanwhile in the 3rd cohort, rates of AD were only significantly higher when 
compared to the healthy control group (20). SAD (55,60,25,20,50), GAD (25,50), 
social phobia (SOP) (50,55,60), specific phobias (SP) (60) and obsessive-compulsive 
disorder (OCD) (25) were also found to be significantly higher compared to the 
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cohort’s control groups. Longitudinal analyses (31) confirmed a significant increase in 
anxiety symptoms during this developmental stage.  
Attention Deficit Hyperactivity Disorder (ADHD). The estimated prevalence in 
OPBD ranged from 4% (13) to 31% (24). Three cohorts found a higher incidence of 
ADHD in OPBD compared to a healthy control group (25,24,50), 1 cohort compared 
to a psychiatrically ill control group (55), and 1 cohort compared to offspring of 
healthy and non-healthy parents as a single control group (60). Two cohorts reported 
no significant differences compared to any of the control groups (13,20). 
Oppositional Defiant Disorder (ODD)/Conduct Disorder (CD).  The prevalence 
rate in OPBD ranged from 0% (13) to 28% (31). For cohorts reporting separately for 
ODD and CD the ranges were 7% (60) to 19% (25) and 2% (32) to 7% (60) 
respectively. Two cohorts observed an increased prevalence in OPBD compared to a 
healthy control group (24,50: only for ODD), and 1 cohorts compared to its combined 
control group (for ODD and CD; 60). Four cohorts did not find any differences 
between (55,25,13,20) and within (i.e. longitudinally; 31) their sample.   
Substance Use Disorders (SUD). The prevalence rate in OPBD ranged from 0% 
(25,13) to 9% (20). No significant difference was found in the SUD incidence 
between OPBD and any type of control group (25,13,20).  
Country of origin 
Two of the 10 cohorts in this stage had a non-USA sample (60,20). The non-USA 
cohorts reported relatively smaller prevalence rates of BPSD in OPBD (2% and 4% 
respectively) compared to the USA cohorts (in all cohorts ≥9%). Neither study 
reported a significant difference in the prevalence of BPSD when compared to the 
control group as opposed to the USA cohorts (55,25,24,13,50). 
Adolescence 
Thirteen cohorts (25,20,50,57,21,59,34,56,58,32,52,62,30) provided data on the 
adolescent developmental stage, with a mean age range from 12 (25,20,50) to 17.9 
(62) years old. Five cohorts had a healthy control group (25,57,34,58,30), 1 cohort a 
psychiatrically ill control group (62), and 2 cohorts had both types control group 
(20,21). In this developmental stage, 1 of the cohorts (34) assessed its sample on 




BPSD. The estimated prevalence in OPBD ranged from 0% (21,32) to 27% (62) and 
from 6% (59) to 7% (30) in cohorts specifically reporting for BD-I. Two cohorts with 
a healthy control group (25,30) and 1 with a psychiatrically ill control group (62) 
reported a significant difference between the groups, with OPBD presenting an 
increased risk for BPSD (25,52), BD-I (30) and cyclothymia (62). Two cohorts with a 
healthy control group (57,58) and 1 with both types of control group (21) found no 
difference in BPSD prevalence between the groups. The current prevalence of BPSD 
in the Bucharest cohort (34) was 1% and was not found to be significantly different 
from the healthy control group. 
UPSD. The lifetime estimated incidence in OPBD ranged from 16% (58) to 34% (25), 
while the current prevalence was 8% (34). MDD ranged from 3% (62) to 22% (32) 
and minor depressive disorders from 3% (59) to 39% (32). Four cohorts found a 
significant higher risk of UPSD in OPBD when compared with a healthy control 
group (25,28: for any mood disorder, 21: only for MDD, 34: current prevalence). Two 
cohorts reported no significant differences in the estimated prevalence of any UPSD 
between OPBD and healthy control group (57,58) and another 2 between OPBD and 
psychiatrically ill control group (21,62).   
Non-Mood Disorders 
AD. The lifetime prevalence in OPBD ranged from 3% (59) to 46% (20,56), while the 
current prevalence was 12% (34). Three cohorts reported a significantly higher risk in 
OPBD for any AD (34: current prevalence,20,25) and specifically for SAD (25), GAD 
(25) and OCD (25) when compared to the healthy control group. The remaining 
cohorts did not observe any differences between OPBD, healthy (57,21,58), and/or 
psychiatrically ill control groups (21,62) in AD prevalence. 
ADHD. The lifetime incidence of OPBD ranged from 5% (52) to 40% (27), while the 
current incidence was 21% (34). Three cohorts (25,21,34: current prevalence) found a 
significantly higher rate of ADHD in OPBD compared to a healthy control group. 
Two cohorts found no difference in the rate between OPBD and healthy control group 
(57,58) and one cohort between OPBD and psychiatrically ill control group (21). 
ODD/CD. The lifetime prevalence in OPBD ranged from 3% (21) to 34% (56) and 
specifically for ODD and CD: 12% (57) to 28% (25) and 3% (59) to 8% (58) 
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respectively. Current prevalence of ODD and CD in OPBD was 3% and 11% 
respectively (34). No cohort with a control group of any type reported a significant 
difference between the groups (25,57,21,34,56,62). 
SUD. The prevalence in OPBD during adolescence ranged from 2% (57) to 19% (62), 
with no cohort reporting a significantly higher risk in the OBPD group compared to 
controls (25,57,58,62).  
Country of origin 
Six of the 13 cohorts in this stage had a non-USA sample (20,57,21,34,58,52). The 
main difference compared to the USA cohorts was observed in the diagnostic 
category of BPSD. Non-USA cohorts reported a prevalence of under 5% and non-
significant difference compared to control group in contrast to the USA cohorts that 
reported a prevalence of above 7% (in 4/5 cohorts) and a significantly higher risk for 
OPBD (25,62,30).   
Early Adulthood/Adulthood 
Seven cohorts (50/23,32,25,20,53-33,54,27) provided psychiatric follow-up data for 
early adulthood/adulthood with a mean age range from 18 (50) to 28 (33) years old. 
Three cohorts had a healthy control group (50/23,25,27) and 1 cohort had a control 
group of both types (20/54). 
Mood Disorders 
BPSD. The prevalence rate in OPBD ranged from 18% (50) to 33% (25) and for BD 
type I or II: 4% (23) to 17% (54). All four cohorts with a control group reported a 
significantly higher risk for BPSD, BD-I and BD-II in OPBD compared to a healthy 
control group (23,25,27) and a psychiatrically ill control group (54).  
UPSD. The prevalence of MDD in OPBD ranged from 10% (53) to 37% (54) and of 
minor mood disorders from 9% (54) to 30% (27). One cohort observed a higher risk 
in OPBD compared to the healthy control group for both categories (23), 1 cohort for 
none of the categories (54), and 1 study only for MDD (27). There were no 
differences reported compared to the psychiatrically ill control group (54). 
Two cohorts reported over half of their sample to experience or have experienced any 
UPSD (25) and any mood disorder (BPSD and UPSD; 20) in their lifetime. This was 




AD. The lifetime prevalence in OPBD ranged from 10% (25) to 48% (20). Three of 
the four cohorts found a significantly higher prevalence of any AD (23,27), SAD 
(23,25), GAD (23,25), SOP (23), panic disorder (PD) (23) and OCD (25) compared to 
the healthy control group. 
ADHD. The lifetime prevalence in OPBD ranged from 5% (53,33) to 22% (25). Two 
cohorts found a significantly higher risk in OPBD compared to a healthy control 
group (23,25). Two did not find a higher risk compared to both healthy (54,27) and 
psychiatrically ill control groups (54). 
ODD/CD. The lifetime prevalence in OPBD ranged from 2% (27) to 7% (33,53). For 
ODD: 15% (54) to 33% (25) and for CD: 10% (23) to 12% (54). Only 1 (23) of the 4 
cohorts with a control group, reported a significantly higher risk in OPBD (vs healthy 
group and only for ODD).   
SUD. The lifetime prevalence in OPBD ranged from 14% (25) to 30% (27). Two of 
the cohorts reported an increased risk compared to the healthy control group (23,27). 
Two did not find any difference (25,54) compared to the control groups. 
Country of origin 
Four of the 7 cohorts in this stage had a non-USA sample (20,53/33,54,27). The main 
differences were spotted in the non-mood disorders where overall the non-USA 
cohorts reported non-significant differences between OPBD and control groups in 
contrast to the USA cohorts. 
Disorder Onset and Clinical Staging Findings 
Two approaches to staging were observed in the literature: staging by reporting of 
rates of disorder or mean age of onset of symptoms prior and/or subsequent to onset 
of BD, and staging by examination of associations between disorders at one point and 
their association with disorder onset at subsequent developmental points. The former 
approach is a less rigorous approach to staging given that mean age masks variance in 
age of onset within cohorts; nevertheless, based on the state of the art of the existing 
literature, we opted to report both staging models so as to gain an insight into broad 
patterns of developmental risk in OPBD.  
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Seven of the cohorts reported data on the onset of mood and non-mood disorders in 
OPBD (23,25-27,30,33,56). Data was reported either in the form of mean age of onset 
of the disorders (cross-sectional cohorts: 25,56,26) and/or of the percentage of OPBD 
exhibiting any given psychiatric disorder prior to onset of BD (longitudinal cohorts: 
30,27,33,23).  
In 2 of the 3 cross-sectional cohorts (25,56) the following pattern of mean age of 
disorder onset was observed in OPBD: non-mood disorders (ADHD, anxiety and 
behavioural disorders); mood disorders (depression, MDD);mania.  
In the 4 longitudinal cohorts the clinical progression of disorders reported for OPBD 
developing BD was the following: non-mood disorders (ADHD, anxiety, behavioural 
and sleep disorders) prior to the 1st episode of mania/hypomania (30,27,33,23) and 
prior to mood disorders (30,27); non-bipolar mood disorders (especially those in the 
depressive polarity) prior to mania/hypomania (30,27,33,23); mania/hypomania; and 
substance use disorder prior (23) or subsequent (27,33) to the 1st hypomanic/manic 
episode.  
The developmental stage of each psychiatric category onset varied considerably, with 
USA cohorts (25,56,26,23) presenting an overall earlier mean onset of disorders 
compared to non-USA and the Amish cohorts (30,27,33). Specifically, all USA 
cohorts (23,25,26,56), except for the Amish cohort (30), reported a pre-pubertal mean 
age of onset of mania/hypomania, or a substantial percentage of OPBD (86%) 
exhibiting the first (hypo)manic episode in childhood (before 12 y. o.). Non-USA 
cohorts (27,33) and the Amish cohort (30) reported a mean age of onset of the first 
BD activation episode in late adolescence/young adulthood.  
Among the longitudinal cohorts that examined cross-lagged associations between a 
precursor disorder at one developmental point and later onset of (hypo) mania, 
childhood anxiety was most consistently related to later manic symptoms (27,30). The 
mean onset of anxiety disorders was almost 10 years prior to the onset of (hypo) 
mania (27,30). In the Pittsburgh cohort (23), DBD, MDD and subthreshold manic/ 
hypomanic episodes were significantly associated to the onset of (hypo)mania. 
However, when statistical analysis was limited to prospective data (for 344/391 
participants), only the subthreshold manic/hypomanic episodes continued to report 
significant prediction for the development of BD in OPBD. 
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Quality Assessment Results 
An assessment of methodological quality for all studies included in the review is 
presented in Table 4 with reporting per AHRQ item and for total score. Papers’ 
percentage score ranged from of 56% (59) to 90% (50,51) with a mean of 73% 
(SD=9,9%). The highest scores for methodological quality were reported for the 
Pittsburgh (23,50,51) and Lausanne cohorts (20,54). The lowest score for 
methodological quality was reported for the Texas cohort (59). Across all studies, the 
main methodological inconsistency was in reporting of sample size, with only 1 study 
(54) conducting and reporting a power analysis, although this may represent omission 
of reporting rather than inadequate power. In addition, only 7 (23,24,30,34,50,51,61) 
of the 20 controlled studies attempted to reduce bias of baseline differences between 
study and control groups and 4 (20,25,31,54) of the rest did so partially (usually 
recruiting the control group based on the same geographical areas). Outcome 
assessment of offspring psychopathology was blind in 16 (13,20,21,23-
25,27,30,34,50,51,54,55,60-62) of the 27 studies and partially blind in another 2 
(31,32), due to the failure in maintaining blindness of parental psychiatric status 
during the follow-up assessment. The rest of the quality checklist items showed less 
heterogeneity, with most studies using a reliable and validated method for measuring 




The current systematic review synthesizes evidence indicating an increased risk of 
developing a wide range of mood and/or non-mood disorders in OPBD in comparison 
to offspring of non-bipolar parents. Our findings update and extend previous reviews 
(12,18,19), and suggest there is additional benefit to appraising this risk through a 
developmental framework. As hypothesized, risk of psychiatric disorder in OPBD 
progresses along a developmental pattern, and data are broadly supportive of a clinical 
staging model. 
As indicated by previous findings (18), we report consistently high rates for OPBD 
experiencing any Axis I disorder across all developmental stages. However, this 
broadly elevated risk, obscures a more complex pattern of risk of specific disorders 
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when the estimated risk and the mean age of onset of specific disorders are placed 
along a developmental continuum. Our revised model (Figure 3) updates previous 
clinical staging models; (27) by proposing that developmental risk in OPBD evolves 
from non-mood disorders in childhood to mood and manic/hypomanic symptoms 
accompanied by recurrent substance use disorders in adolescence and early adulthood. 
However, we note that the current evidence for risk in OBPD is still reliance to a large 
extent on cross-sectional data within time periods, and that the data on true clinical 
staging -  i.e. modelling of a sequential pattern of risk across developmental periods to 
a number of ‘end-state’ psychiatric disorders (including BD) – is still limited. 
Therefore, our discussion focuses on the broad patterns of developmental risk 
identified in the review.   
Clinical Stage 1: Non-Mood Disorders 
Consistent with earlier models (27,40), Stage 1 is characterized by the onset of non-
mood disorders in OPBD during early and middle childhood. These findings support 
possible neurodevelopmental vulnerabilities in OPBD (29). However, although OPBD 
are reported as vulnerable to a number of anxiety and behavioral disorders 
(ADHD/ODD/CD) during this developmental stage, our synthesis of the longitudinal 
data suggests that to date, only anxiety disorders are predictive of later BD onset 
(27,30). Therefore, although anxiety disorders are viewed are a precursor in most 
OPBD cases that go on to develop BD, not all OPBD’s who have anxiety in childhood 
go on to develop BD. Consequently, anxiety may not be robust as indicator, unless 
supplemented by additional data on other risk factors. 
Clinical Stage 2-3: Mood Disorders 
In contrast to earlier models (27,40), our synthesis suggests that developmental risk in 
adolescence may be more accurately represented by a broad “Mood Disorders” stage, 
without delineation into minor and major non-bipolar mood disorders. This may be 
more parsimonious, given that the current review identifies no significant differences 
between estimated prevalence and onset of minor (dysthymia, adjustment disorder 
with depressed mood, and DD NOS) and major (MDD) mood disorders in OPBD. We 
also emphasize that mood disorders, particularly depressive disorders, consistently 
precede the onset of manic/hypomanic episodes both in longitudinal and cross-
sectional studies (23,25,27,30,33,56). In contrast to previous papers (27,40) we 
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synthesized both prospective and retrospective data, and as such, we suggest that a 
broader mood disorders category may have greater clinical utility than delineation into 
narrower bandings. However, we also note that particularly this stage relies upon a 
combination of developmentally sensitive measurement tools (e.g. K-SADS-PL, K-
SADS-E) and recall bias of informants (typically parents for children under 16 y.o.), 
that may influence the identification of minor internalizing symptoms retrospectively, 
especially when followed by externalizing and major disturbances (33,66). Moreover, 
although evidence suggests that manic symptoms are more accurately reported by 
caregiver reports than by self- or teacher reports (67), in OPBD samples parental 
mental state may be a confound in assessing OPBD functioning and health status 
(68,69). We also note that labelling of mood and anxiety disorders vary considerably 
between studies (e.g. unipolar depression, minor depressive disorder, major 
depressive disorder) and as such it may be difficult to identify clear patterns for 
specific sub-classes of non-bipolar mood disorder in OPBD until further large datasets 
emerge. 
Clinical Stage 4: Mania/Hypomania 
Consistent with existing models (27,40) our review supports a final stage (Stage 4) 
representing the onset of “Mania/Hypomania”, for some OPBD individuals. Similar to 
our concerns regarding labelling of mood disorders we also note that the existing 
literature uses the terms BD, BPSD and Mania/Hypomania interchangeably. This 
introduces a potential lack of specificity regarding sub-type of BD assessed and 
separation first manic/hypomanic symptoms from BD onset. There are also 
implications for diagnostic accuracy, given that index incidence of mood symptoms in 
BD often occurred via a depressive episode (23,27,33). We suggest that specificity of 
the predictive utility of this stage will increase as more cohorts report adult follow-up 
data. 
We also observed that our findings indicate a divergence in the mean age of BD onset 
between USA and non-USA OPBD cohorts, suggesting that sociocultural background 
could be a moderating factor in the development of BPSD. It is possible that findings 
may differ in USA cohorts due to reporting bias related to the assessment of broader, 
subthreshold bipolar spectrum syndromes (i.e. BDNOS); sample selection bias related 
to mental health system accessibility (33); and increased prescription of antipsychotic 
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and mood stabilizing drugs for underage individuals in USA (70). This highlights that 
cultural aspects in the aetiology and reporting of risk may also be relevant. 
Recurrent Substance Use Disorder 
We identified a gradual increase from middle childhood to early adulthood in 
substance use disorder (SUD) amongst OPBD, along with an elevated risk compared 
to offspring of healthy parents during the last developmental stage. In addition, based 
on preliminary clinical staging data stemming from longitudinal studies (23,27,33) , 
our review provides evidence for SUD co-occurring with BD with an onset either 
prior or subsequent to the onset of manic/ hypomanic symptoms. Elevated prevalence 
of comorbid SUD and BPSD has been documented both in community (71-73) and 
clinical studies (74,75) and longitudinal studies following OPBD from childhood to 
early adulthood have underlined that risky behaviors may be a marker pf emergent 
psychiatric disorder in OPBD (76). Shared mechanisms and overlapping 
neurobiological pathways such as impulsivity, susceptibility to behavioral 
sensitization, impaired coping skills, and responses to rewarding stimuli suggest a 
complex bidirectional interaction between SUD and BD (77,78). Substance use has 
been proposed to increase the risk of BD development by “unmasking” subthreshold 
symptoms to a clinically significant level (79,80); inversely, substance use has been 
theorized as a method of coping with unpleasant affective symptoms (“self-treatment 
strategy”; 81,82). Both SUD and BD may also be triggered by stressful life events 
(83,84), potential via epigenetic mechanisms.  
Regardless of directionality, comorbid substance use is associated with a more 
complicated diagnosis, prognosis and treatment of BD (85) and the presence of SUD 
may obscure the diagnosis of BD, as intoxication by or withdrawal from substances 
can mimic depressive, manic and anxious states (86). Therefore, our data support a 
need for integrating assessment and if indicated early intervention for SUD in OPBD 
may confer benefits for management of broader psychiatric disorder in this high-risk 
group.   
Limitations 
There are a number of limitations in the present review. Firstly, the developmental 
patterns of risk found to occur in OPBD, should be interpreted with caution as most of 
the included studies have a cross-sectional design, and the majority of OPBD have not 
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yet passed through the peak risk period for developing BD. Secondly, the 
methodological heterogeneity of studies may have influenced the overall findings; 
specifically small sample sizes and the lack of control groups in some of the cohorts, 
may have substantially inflated estimates of risk of psychopathology in OPBD. 
Nevertheless, our quality assessment of the literature indicated a methodologically 
robust corpus of studies. Thirdly, the exclusion of dimensional outcomes in OPBD, 
although applied in order to ensure a comparable baseline between studies, also 
resulted in omission of subthreshold symptoms BD symptoms (e.g. 13). Finally, 
although we identified studies from Canada, USA, South America, Europe and 
Western Asia, our own inclusion criteria and the current status of the field may limit 
the cross-cultural validity and applicability of our findings to the global youth.   
Implications for Research 
Our review underline the importance of developmental continuity in understanding 
the risk of psychopathology and adoption of a developmental framework when 
assessing at-risk cohorts. However, upscaling developmental research in ultra-high-
risk offspring requires tighter methodologies. For instance, assessment and reporting 
of the mean age of onset of a disorder and of the current estimated prevalence would 
enable researchers to better delineate risk at specific developmental stages. In 
addition, using combined data from complementary sources of information (e.g. 
caregivers, teachers, self-reports) could enhance the accuracy of findings (68,69).  
Our evidence supports and extends existing developmental psychopathology 
frameworks (27,40). However, bearing in mind the limited available data and 
heterogeneity of the studies included in this systematic review, further research is 
required to improve the evidence-base and generalizability of this model, particularly 
with regard to longitudinal cohorts. This would enable the field to more confidently 
comment on continuity/discontinuity of risk between developmental periods and also 
relate developmental findings to outcomes for the peak risk period for BD onset as 
has been noted for the literature on risk in offspring of schizophrenia-diagnosed 
parents (64,65). Furthermore, there is a parallel literature on neurophysiological 
markers for BD risk endophenotypes (87-89). In this regard, OPBD cohorts offer an 
ideal research opportunity for examining the role of (i) the underlying epigenetic 
mechanisms in OPBD according to developmental stage (ii) the mediating and 
moderating factors contributing to the development of BD (e.g. sociocultural 
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background and substance use, as suggested by this review), and (iii) the 
resilience/protective factors of OPBD presenting no clinical symptoms. 
Implications for Clinical Practice 
With regards to clinical implications, our review reiterates the value of considering 
family mental health status of individuals as markers for both risk and resilience. 
Health professionals (including but not limited to mental health) engaging with adult 
BD-diagnosed individuals, but also with children and young people, should be aware 
of the high-risk profile of OPBD and its dynamic nature through development. 
Parents with BD and co-caregivers should also be provided with information about 
the factors that may set their offspring at-high-risk for developing maladaptive 
behaviors, encouraged to seek professional help if necessary, and offered a systematic 
support and psychoeducation for maintaining the balance between parenting and 
mental health issues. Additionally, children and young people presented in clinical 
settings that are offspring of parents with BD should be monitored for potential early 
markers of risk, and offered early intervention where indicated. The clinical staging 
model thus offers a promising framework for utilizing developmental “opportunity 
windows” linked to optimally needs-matched interventions (42). For instance, our 
preliminary evidence indicating childhood anxiety disorders and depression in 
adolescence as potential early markers of BD in OPBD (23,27,30,33), offers the 
opportunity for development and implementation of psychological interventions, 
including caregivers where appropriate, over medication prescription, given the 
association of antidepressants and stimulants to the onset of BD (70). Finally, a move 
towards early intervention and primary prevention within OPBD, would link to 
broader strategies acknowledging the public health importance of mental health, both 
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Table 1 (p. 36-38) provides details on the characteristics of the included studies, 
grouped into cohorts. The characteristics provided within the table include: cohort 
name, first author name, citation, year of publication, country, parental characteristics 
(N, Gender), offspring characteristics (N, Gender, Mean Age), assessment 
characteristics (DSM measure, assessment tool for parents and for offspring) and if 
any, follow-up in years and type of control group. 
Table 2 (p. 39) presents the heuristic framework used in the review to present results 
for estimated psychiatric risk in offspring of parents with bipolar disorder (OPBD). 
The broader categories of psychiatric disorders used are mapped with the specific 
disorders assessed in at least one of the included papers.  
Table 3 (40-44) presents the results of the included studies on the psychiatric risk of 
OPBD. Findings are placed on a continuum of 5 different developmental stages based 
on the mean age of the cohort (early childhood 0-6 y.o., middle childhood 6-12 y.o., 
adolescence 12-18 y.o., early adulthood 18-23 y.o., adulthood >23 y.o.). Risk is 
separately reported for any Axis I Disorders, Mood and Non-Mood Disorders.  
Table 4 (45-47) displays evidence on the sequential onset of mood and non-mood 
disorders in relation to the onset of mania/hypomania; i.e. clinical staging of bipolar 
disorder (BD). Associations between a disorder at a certain developmental stage and 
later onset of BD are highlighted using bold typeset. 
Table 5 (48-50) shows the quality assessment results of each study per AHRQ 
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Massachusetts #1 USA  88 -  117 F=50 13.6 (5.3)  DSM-IV SCID K-SADS-E, N/A 
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Notes: All percentages are rounded; †Adapted version of WASH-U-KSADS; ‡Some of the demographic information derive from Radke-Yarrow et al., 1998 (63); *Studies with control group; 
ᵃControl group of healthy parents; ᵇControl group of non-healthy parents; ᶜControl groups of both healthy and non-healthy parents; ᵈFrench version; ᵉSpanish version; ᶠTurkish version; ᶢ 
Brazilian version; ' Sample is consisted from Henin et al., 2005 (25) sample and a subsequent sample; ²Each offspring comes from an independent family; ³Clinical population; CAS: Child 
Assessment Schedule; CBCL: Child Behaviour Checklist; DIGS: Diagnostic Interview for Genetic Studies; DSM: Diagnostic and Statistical Manual of Mental Disorders; F: Female; IDCL: 
International Diagnostic Checklists; K-SADS: Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children; K-SADS-E: Schedule for Affective Disorders and 
Schizophrenia for School-Age Children-Epidemiological version; N/A: Not Applicable: Cross-Sectional Study design; SADS: Schedule for Affective Disorders and Schizophrenia; K-SADS-
PL: Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children- Present and Lifetime Version; SADS-L: Schedule for Affective Disorders and Schizophrenia, Lifetime 
version; ; RDC: Research Diagnostic Criteria; SD: Standard Deviation; SADS-LB: Schedule for Affective Disorders and Schizophrenia, Lifetime version for Bipolar Disorder; SCID: Structured 
Clinical Interview for DSM; SD: Standard Deviation; WASH-U-KSADS: Washington University Schedule for Affective Disorders and Schizophrenia for School-Age Children; T1: Time 1; T2: 
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Table 2. Categories of disorders measured in included papers mapped with specific disorders. 
 
Bipolar Spectrum Disorders Unipolar Spectrum Disorders Anxiety Disorders Behaviour Disorders Other Disorders 
Bipolar type I disorder (BD-I)  
Major: 
Generalized anxiety disorder 
(GAD) 
Oppositional Defiant Disorder 
(ODD) 
Substance use disorder 
(SUD) 
Bipolar type II disorder 
(BD-II) 
Major depressive disorder (MDD) Separation anxiety disorder 
(SAD)  
Conduct Disorder (CD) Sleep disorder (SLD) 











Cyclothymia (Cycl.) Dysthymia Overanxious disorder   
 Adjustment disorder with 
depressed mood 
Simple/Specific phobias (SP)   
 Depression not otherwise specified Social phobia (SOP)   
  Panic disorder (PD)   





Table 3: Risk of Psychopathology in OPBD 
Cohort 













with Axis I 
Diagnoses 







Behaviour Disorders Other 
Disorders  ADHD ODD/CD 
















2010 3.8 26%* 2% NS 
BD- NOS 
1% NS  11% NS 
 
16%* ODD: 12% (p<0.07) 
CD: 2% NS 
SLD: 3 NS 
Los Angeles 
CI (32) 
1990 0-4 1% ᵃ - Major: 0%   - - - - 
Rockville 
Lifetime (61) 
1988 5-6 86% - 43%  14%-43% - CD: 43% - 
Minnesota 
Lifetime (31) 
1992 5.6 - - 24% †  9% - 24% † - 
Lausanne  
CI (20) 
2012 6 - 21% (any mood disorder)  29% - - - 
 Middle Childhood 
Minnesota 



















2006 7.1 - 9%* 
BD-I: 6%* 
Major: 9% NS 
Minor: 3% NS 




ODD: 9% NS 






2005 8 - 9 %* 
BD-I 
23%*  3%-18%* 22% * ODD: 19% NS 





1990 5-9 32% ᵃ - Major: 6%   - - - - 
Minnesota 
Lifetime (31) 
1992 9.2 - - 44% †  44% † - 28% - 
Ohio 
Lifetime (24) 
2007 10.2 78%* 
 
38%* 
BD-I: 16% NS 
Major: 14% NS 
Minor: 14% NS 

















0% NS SUD: 0% 
Stanford 
Lifetime (26) 
2000 11.1 55% 15% 
BD or Cycl. 
15%  8% 28% ODD: 10% - 
Sao Paulo  
Lifetime (60) 





2012 11.8 62%* 
 
4% NS 









2009 11.9 52%* 11%* 
BD-I: 2%* 
Major: 9%* 
Minor: 2% NS 
 26%* 25% * ODD: 17% * 






2005 12 - 12%* 34%*  4% - 21%* 22%* ODD: 28% NS 
CD: 6% NS 




2012 12 - 28%* (any mood disorder)  46%* - - - 
Pittsburgh 
CI (50) 





2013 12.2 50% * 4% NS Major: 6% NS  14% NS 18% NS ODD: 12% NS SUD: 2% NS 
Barcelona #2 
Lifetime (21) 





Minor: 9% NS 
 12% NS 18%* 
 
3% NS - 
Texas 
Lifetime (59) 

















 12%* 21%* ODD: 3% NS 





2015 13.4 - 21% 25%  46% 27% 34% - 
Istanbul 
Lifetime (58) 
2015 14.2 48%* 4% NS 16% NS  12% NS 8% NS CD: 8% NS SUD: 8% NS 
Los Angeles 
CI (32) 
1990 10-14 52%ᵃ - Major: 20%   - - - - 
Los Angeles 
Lifetime (32) 
1990 16.6 72% 0% Major: 22% 
Minor: 39% 
 11% - 17% 6% 22% SUD: 11% 
Dutch 
Lifetime (52) 
2004 17.4 49% 
 
5% 
BD-I or BD-II: 4%  
Major: 8%  
Minor: 22% 
 11% 5% 7% SUD: 9% 
Illinois 
Lifetime (62) 
1985 17.9 43% ** 27%** 
Cycl.: 24%** 
Major: 3% NS 
Minor: 8% NS 
 5% NS 
 







- 7%*  
BD-I 
-  - - - - 
 Early Adulthood 
Pittsburgh 
CI (50) 
2009 18 - 18% Major: 24%  - - - - 
Pittsburgh 2015 18.1 74%* 19%* Major: 19%*  40%* 31%* ODD:25%* SUD:20%* 
44 
 
Lifetime (23) BD-I: 4%* Minor: 10%* CD:10% 
Los Angeles 
CI (32) 
1990 15-19 76%ᵃ - Major: 33%   - - - - 
Massachusetts #1 
CI (25) 
2005 18 - 33%* 51% *  10% - 
21%* 





2012 18 - 64%* (Any mood disorder) 
 
 48% * - - - 
Dutch 
Lifetime (53) 
2005 21 59% 
 
10% 
BD-I or BD-II 
Major: 10% 
Minor: 24%  
 21% 5% 7% SUD:16% 
Lausanne 
Lifetime (54) 
2016 21.1 - 17% **   
BD-I or BD-II 
Major: 37% NS 
Minor: 9% NS 
 44% NS 
 






2014 22.6 - 22%* 
 
Major: 32%* 
Minor: 30% NS 





2013 28 72% 13% 




 25% 5% 7% SUD: 23% 
Notes: All percentages are rounded; Bipolar Spectrum Disorders include: Bipolar type I disorder (BD-I), Bipolar type II disorder (BD-II), Bipolar disorder not otherwise specified (BD-NOS), 
Cyclothymia (Cycl.); Unipolar Spectrum Disorders include: Major: Major depressive disorder; Minor: Dysthymia, Adjustment disorder with depressed mood, Depression not otherwise 
specified; Anxiety Disorders include: Generalized anxiety disorder, Separation anxiety disorder, Obsessive compulsive disorder, Overanxious disorder, Post-traumatic stress disorder, Social 
phobia, Panic Disorder, Simple/Specific phobias; ADHD: Attention Deficit Hyperactivity Disorder; ODD: Oppositional Defiant Disorder; CD: Conduct Disorder; SLD: Sleep Disorder; SUD: 
Substance Use Disorder; CI: Cumulative Incidence (Confidence Interval 95%); *Significantly different compared to non-psychiatric control group (at least p <0.05); **Significantly different to 
psychiatric control group (at least p< 0.05);  *** Significantly different compared to both control groups as a whole (at least p <0.05); NS: Non significant; -: Not measured; †Significantly 














































3.7 (2): ADHD 
4.6 (2.8): AD 
7.4 (3.7): DBD 
8.9 (4.2): Depression 9.3 (5): Mania 

















0-6: Crying, hyper-alert, anxiety/worry, somatic 
complaints 
7-12: Increased anxiety type symptoms, decreased 
sleep and energy, mood lability, fearfulness, role 
impairment 





5 (20): ND 
9.4 (10): DBD 





(27) 7-30 9.8 (4.2): AD 
9.9: SLD 
17.5 (3.1): SUD 
18.4: Psychotic disorder 
 










17.1 (8): comorbid AD (67% 
prior) 
17.7 (1.5): comorbid SUD 
(in every case prior) 
 
14.6 (4.7) 
(in every case prior, for 
88% in the depressive 
polarity) 
17.3: Hypomania 









ADHD (42% prior) 
AD (53% prior) 
DBD (48% prior) 
 
12.5 (4.6): Depressive 
episode (70% prior) 




(36% prior)  
 
13.4 (3.8) ᵈ: 
Mania/Hypomania 
(12.1 (4): BD) 
SUD (94% subsequent) - 
Notes: All percentages are rounded; Mood disorders do not include bipolar disorder, manic or hypomanic episode; Text in bold: Predictive association to first (hypo)manic episode; AD: 
Anxiety Disorders; ADHD: Attention deficit hyperactivity disorder; BD: Bipolar disorder; CD: Conduct Disorder; DBD: Disruptive Behavior Disorders (includes ODD/CD); MDD: Major 
Depressive disorder; ND: Neurodevelopmental disorders, which include ADHD, learning disorder and Cluster A traits; ODD: Oppositional Defiant Disorder; SD: Standard Deviation; SLD: 
Sleep disorder; SUD: Substance Use Disorders; ᵃIn case of longitudinally followed cohorts, data from the most recent follow-up are reported; ᵇNone of the participants had pre-pubertal manic or 
hypomanic episode; ᶜ29% pre-pubertal onset of depressive episode; ᵈ86% pre-pubertal onset of manic episode; * Detailed age of onset derive from Massachusetts #2 paper (55); ** In cases of 














































































































































































































































































2015 (23) *  
Y Y N Y Y Y Y Y P Y Y 19 86% 
Birmaher 
2010 (51) 
Y Y N Y Y Y Y N/A Y Y Y 18 90% 
Duffy 
2014 (27) * 
Y N N Y Y Y Y Y N Y Y 16 73% 
Reichart  
2004 (52) 
Y N/A N P Y Y N Y Y N Y 13 65% 
Hillegers  
2005 (53) 
Y N/A N Y Y Y N Y Y N Y 14 64% 
Mesman  
2013 (33) 
Y N/A N Y Y Y N Y Y P Y 15 75% 
Egeland   
2012 (30) * 
Y Y N N P P Y Y Y N Y 14 64% 
Vandeleur  
2012 (20) * 





Y P Y Y Y Y Y Y N Y Y 19 86% 
Henin 
2005 (25) 




Y N N Y Y Y Y N/A N Y Y 14 70% 
Freed 
2015 (56) 
Y N/A N Y Y Y N N/A Y Y Y 14 78% 
Garcia-Amador 
2013 (57) * 
Y N N Y Y Y N N/A N Y Y 12 60% 
Sanchez-Gistau 
2015 (21) 
Y N N Y Y Y Y N/A Y Y Y 16 80% 
Erkan 
2015 (58) * 
Y N N Y Y Y N N/A N Y Y 12 60% 
Zappitelli  
2011 (59)  
Y N/A N Y Y Y N N/A N P P 10 56% 
Petresco 
2009 (60) * 
Y N N Y Y Y Y N/A Y Y Y 16 80% 
Singh  
2007 (24) * 
Y Y N Y Y Y Y N/A N Y Y 16 80% 
Findling  
2006 (13) * 
P N N Y Y Y Y N/A N Y Y 13 65% 
Chang 
2000 (26) 
Y N/A N Y P Y N N/A N Y Y 11 61% 






Y N N Y Y P P Y P Y Y 15 68% 
Grigoroiu-
Serbanescu 
1989 (34) * 
Y Y N Y P Y Y N/A Y Y Y 17 85% 
Zahn-Waxler 
1988 (61) 
N Y N Y Y Y Y Y Y N P 15 68% 
Klein 
1985 (62)  
Y N N Y Y Y Y N/A N Y P 13 65% 
Notes: Y= Yes; N=No; P=Partially, N/A: This question was not applicable for the study; *Independently rated by a second researcher 
 
 
 
